7-Jul-2025	MST Access Report \| Exosome Tech Leader: Next-Gen Diagnostics and Therapeutics

17-Dec-2024	MST Access Report \| CAR-NK-exosome in-vitro proof of concept for breast cancer

6-Dec-2024	MST Access Report \| Ovarian cancer biomarker validation

27-Aug-2024	MST Access Report \| FY24: Solid Progress; Exosome Therapeutics Key Program to Watch

21-Aug-2024	MST Access Report \| NEURO-NET validated for Parkinson's Disease EV isolation

9-Aug-2024	MST Access Report \| Ready to Fund Key FY25 Priorities

5-Jun-2024	MST Access Report \| Engineered Exosomes Kill Breast Cancer Cells In-vitro

7-May-2024	MST Access Report \| Leveraging Exosome Advantage

28-Feb-2024	MST Access Report \| SubB2M/CA15-3 test: beats leading breast cancer test by 19%

6-Nov-2023	MST Access Report \| 1Q: Good cash runway as a new year of catalysts gets underway

7-Sep-2023	MST Access Report \| EXO-NET agreement with CDO to grow US revenue opportunity

7-Jul-2023	MST Access Report \| Global Joint Marketing Agreement: Major Boost to EXO-NET® Profile

28-Jun-2023	MST Access Report \| SubB2M/CA15-3 Test: Striking Study Results in Breast Cancer

13-Feb-2023	MST Access Report \| Good signs of progress in 2Q, SubB2M breast cancer study data

14-Dec-2022	MST Access Report \| OC97 study confirms EXO-NET utility for EV biomarker discovery

29-Nov-2022	MST Access Report \| EXO-NET kicks off in US; exosome work centralised in Melbourne

7-Nov-2022	MST Access Report \| 1 1QFY23 closes with healthy cash balance

19-Oct-2022	MST Access Report \| IIQ agrees to develop SubB2M test targeting pan-cancer diagnostic

25-Aug-2022	MST Access Report \| Next-Gen Precision Diagnostics